Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonis C Antoniou

Showing results (81-90 of 319) with videos related to

Pageof 32
Sort By:
Nature Genetics|April 28, 2012
Germline RAD51C mutations confer susceptibility to ovarian cancerChey Loveday, Clare Turnbull, Elise Ruark, et al.
Cancers|June 10, 2023
Co-Creation of Breast Cancer Risk Communication Tools and an Assessment of Risk Factor Awareness: A Qualitative Study of Patients and the Public in IndiaDivya Pillai, Jyoti Narayan, Aleksandra Gentry-Maharaj, et al.
Journal of Personalized Medicine|September 28, 2021
Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?Nora Pashayan, Antonis C Antoniou, Andrew Lee, et al.
BJC Reports|June 3, 2026
Contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM pathogenic variant carriers in two large cohort studiesIsaac Allen, Nancy Whish, Siddhartha Yadav, et al.
British Journal of Cancer|February 3, 2023
Proactive breast cancer risk assessment in primary care: a review based on the principles of screeningJuliet A Usher-Smith, Sarah Hindmarch, David P French, et al.
JMIR Formative Research|January 27, 2019
The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability TestingLouisa L Lo, Ian M Collins, Mathias Bressel, et al.
Breast Cancer Research and Treatment|June 11, 2008
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriersAmanda B Spurdle, Andrew J Deans, David Duffy, et al.
Breast Cancer Research and Treatment|February 25, 2016
iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and managementIan M Collins, Adrian Bickerstaffe, Thilina Ranaweera, et al.
JNCI Cancer Spectrum|May 12, 2021
Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk ModelsSherly X Li, Roger L Milne, Tu Nguyen-Dumont, et al.
Journal of the National Cancer Institute|January 24, 2018
Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population WomenRanjit Manchanda, Shreeya Patel, Vladimir S Gordeev, et al.
Pageof 32

Showing results (81-90 of 319) with videos related to

Sort By:
Pageof 32
Nature Genetics|April 28, 2012
Germline RAD51C mutations confer susceptibility to ovarian cancerChey Loveday, Clare Turnbull, Elise Ruark, et al.
Cancers|June 10, 2023
Co-Creation of Breast Cancer Risk Communication Tools and an Assessment of Risk Factor Awareness: A Qualitative Study of Patients and the Public in IndiaDivya Pillai, Jyoti Narayan, Aleksandra Gentry-Maharaj, et al.
Journal of Personalized Medicine|September 28, 2021
Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?Nora Pashayan, Antonis C Antoniou, Andrew Lee, et al.
BJC Reports|June 3, 2026
Contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM pathogenic variant carriers in two large cohort studiesIsaac Allen, Nancy Whish, Siddhartha Yadav, et al.
British Journal of Cancer|February 3, 2023
Proactive breast cancer risk assessment in primary care: a review based on the principles of screeningJuliet A Usher-Smith, Sarah Hindmarch, David P French, et al.
JMIR Formative Research|January 27, 2019
The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability TestingLouisa L Lo, Ian M Collins, Mathias Bressel, et al.
Breast Cancer Research and Treatment|June 11, 2008
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriersAmanda B Spurdle, Andrew J Deans, David Duffy, et al.
Breast Cancer Research and Treatment|February 25, 2016
iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and managementIan M Collins, Adrian Bickerstaffe, Thilina Ranaweera, et al.
JNCI Cancer Spectrum|May 12, 2021
Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk ModelsSherly X Li, Roger L Milne, Tu Nguyen-Dumont, et al.
Journal of the National Cancer Institute|January 24, 2018
Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population WomenRanjit Manchanda, Shreeya Patel, Vladimir S Gordeev, et al.
Pageof 32